<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670423</url>
  </required_header>
  <id_info>
    <org_study_id>0803-17; IUCRO-0204</org_study_id>
    <nct_id>NCT00670423</nct_id>
  </id_info>
  <brief_title>A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation</brief_title>
  <official_title>A Phase I Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer E. Schwartz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine the highest dose of bortezomib, a new drug for
      graft-versus host disease prevention, that can be given in combination with sirolimus and
      Tacrolimus, without causing severe side effects. This research is being done because there is
      no treatment that is 100% effective in preventing graft versus host disease.

      The goals of this study are to:

        1. Collect peripheral blood stem cells (PBSCs) from donors for transplant.

        2. Determine the largest possible dose of bortezomib that can be given to recipients with
           various blood cancers in a safe manner.

        3. Monitor the recipient for risk of infection or side affects associated with the
           transplant.

        4. Monitor the recipient for increased immunity following transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the maximum tolerated dose (MTD) of bortezomib in combination with tacrolimus and sirolimus as GVHD prophylaxis in patients undergoing myeloablative allogeneic peripheral blood stem cell transplantation.</measure>
    <time_frame>Baseline through end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the toxicity of bortezomib</measure>
    <time_frame>Baseline through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe engraftment</measure>
    <time_frame>Baseline through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the incidence of acute and chronic GVHD</measure>
    <time_frame>Baseline through end of study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Peripheral Blood Stem Cell Transplantation</condition>
  <condition>Transplantation, Homologous</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)</description>
    <other_name>Prograf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)</description>
    <other_name>Rapamune®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:
Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3
Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3
Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3</description>
    <other_name>Velcade®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing myeloablative peripheral blood stem cell transplantation

          -  Have an HLA matched-related or matched-unrelated donor (9/10 antigen or allelic
             mismatch or 10/10 HLA match permitted).

          -  Hematological malignancy including patients with: AML, ALL, NHL, Hodgkin's Disease,
             CLL, CML, MDS and Multiple Myeloma

          -  Meeting institutional standard criteria for allogeneic PBSC transplantation

        Exclusion Criteria:

          -  Patient has &gt;Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  History of autologous or allogeneic transplantation

          -  Evidence of HIV seropositivity

          -  Evidence of active infection

          -  Patients with cardiac dysfunction as described in the protocol

          -  Patients with hypersensitivity to bortezomib, boron or mannitol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jennifer E. Schwartz</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Acute Graft Versus Host Disease</keyword>
  <keyword>Allogeneic Peripheral Blood Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

